In this issue
Jump to section
Related Articles
Cited By...
- The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer
- Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy
- Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors
- Differential diagnosis of lung lesion in breast carcinoma: a metachronous neoplasm or metastasis?
- Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
- Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor-Positive Breast Cancer
- Intratumoural inflammation and endocrine resistance in breast cancer
- Discordance in Hormone Receptor Status Among Primary, Metastatic, and Second Primary Breast Cancers: Biological Difference or Misclassification?
- Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- Assessment of Progesterone Receptors in Breast Carcinoma by PET with 21-18F-Fluoro-16{alpha},17{alpha}-[(R)-(1'-{alpha}-furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione
- Molecular Alterations Between the Primary Breast Cancer and the Subsequent Locoregional/Metastatic Tumor
- Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1
- Global Characterization of the SRC-1 Transcriptome Identifies ADAM22 as an ER-Independent Mediator of Endocrine-Resistant Breast Cancer